Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease

Fig. 3

Multi-omics validation of network-predicted risk genes for Alzheimer’s disease (AD). Circle plot shows all 103 predicted AD risk genes validated by multiple-scale biological evidence. In total, 8 types of biological evidence were evaluated: (1) Brain-expression specificity derived from GTEx database (z-score > 0 as a high brain-specific expressed gene); (2) literature evidence validation for the gene associated with AD; (3) drug target information; (4) literature-derived experimental data from Open targets database; (5) high-quality experimentally validated AD-associated genes; (5–8) transcriptomics-based evidence (Table S3): (6) differential expression (DE) in AD patient brains; (7) differential expression in brain microglia cells of 5XFAD mouse model; (8) differential expression in brain hippocampus of Tg4510 mouse model. Gray bar denotes the number of biological evidence. A total of 13 selected risk genes involved in four AD key pathways are highlighted by red: including regulation of neurotransmitter transport, Aβ metabolic process, long-term synaptic potentiation, and oxidative stress

Back to article page